17.03.2021Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release
17.03.2021Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release
12.03.2021Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release
02.03.2021Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety

Press Release
18.02.2021 Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

Press Release
16.02.2021Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model

Press Release
25.01.2021Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

Press Release
05.01.2021Aura Biosciences Appoints David Johnson to Its Board of Directors

Press Release
22.10.2020F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim

Press Release
13.10.2020Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs

Press Release